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In a “Letter to the Editor” by Yanez et al. [1], 8 cases of
post-transplantation lymphoproliferative disorder (PTLD)
were reported, 5 occurring between December 2011 and
June 2012. This prompted the authors’ center to stop using
Thymoglobulin (Genzyme Polyclonals, Lyon, France) for
graft-versus-host disease prophylaxis in allogeneic hemato-
poietic stem cell transplantation.
The authors speculate that the higher incidence of PTLD
seen at their center was due to a change in the manufacturing
process of Thymoglobulin, leading to a change in the product’s
potency. In particular, the authors’ state that in 2007 a change
in the quantity of the thymic source for rabbit immunization
for Thymoglobulin production was undertaken without clin-
ical validation. Sanoﬁ would like to address the authors’
claims concerning the safety aspects, manufacturing process,
and potency testing of Thymoglobulin and the regulatory
steps required for approval of such changes.
Thymoglobulin safety is evaluated on a regular basis, and
periodic updates are submitted to health authorities by the
company’s pharmacovigilance department. Unsolicited
reporting rates of PTLD from 2008 to 2014 were comparable
with earlier reporting rates observed from 2004 to 2007. In
reported cases of PTLD, Thymoglobulin was often used in
combination with other immunosuppressive agents. The
type and intensity of the immunosuppressive therapy may
vary across patients and institutions and might impact the
risk of developing PTLD.* Correspondence and reprint requests: Suzanne Janssen, Sanoﬁ, Airport
Plaza-Montreal Building, Leonardo Da Vincilaan 19, B-1831 Diegem,
Belgium.
E-mail address: suzanne.janssen@sanoﬁ.com (S. Janssen).
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changes in the Thymoglobulin manufacturing process is not
substantiated. The reduction of the number of thymic cells
used to immunize rabbits used to make Thymoglobulin does
not impact on the quality of the ﬁnal product. All parameters
indicative of a potential change in the nature of both serums
and ﬁnal products have been evaluated, and following a
strictly regulated procedure, the manufacturing process
updates were submitted to and approved by the Health
Authorities of all 68 countries where Thymoglobulin is
registered. Tests of the biological activity for horse and rabbit
antithymocyte globulins are described in the Monograph of
Antithymocyte Globulins [2]. The standard method to eval-
uate biological activity of antithymocyte globulins, according
to the current European monograph, is complement
dependent cell lysis. This required release test is stable, well
controlled, validated, and approved by Health Authorities
worldwide. Released lots are tested on a regular basis during
the shelf-life of thymoglobulin.
Sanoﬁ is committed to producing high-quality products
that meet or exceed established regulatory requirements in
place to ensure safe and efﬁcacious patient care.
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